维普中文期刊产品整合服务
517篇 您的检索式:作者名="Oppermann"
    题名 作者 年代 出处 被引量
1白芨应用于大鼠实验性肝细胞癌介入治疗的研究显示文摘目的比较白芨和免疫反应调节剂、抗血管生成药物在介入经肝动脉化疗栓塞术(transarterialchemoembolization,TACE)治疗ACI大鼠肝细胞癌实验中的疗效。方法在70只♂ACI大鼠肝包膜下植入MorrisHepatom3924A肝癌瘤块(2mm3),移植术后13d进行磁共振(MRI)检查,测量肿瘤体积V1,第14天时,经腹部切开术及胃十二指肠动脉逆行插管至肝动脉而采取以下介入治疗方案(A)丝裂霉素+碘油+肿瘤坏死因子(TNFα)+白介素2(IL2)(n=10);(B)丝裂霉素+碘油+链球菌提取物(OK432)+IL2(n=10);(C)丝裂霉素+碘油+烟曲霉素(TNP470)(n=10);(D)丝裂霉素+碘油+血管内皮抑素+endostatin)(n=10);(E)丝裂霉素+碘油+白芨(n=10);(F)丝裂霉素+碘油+白芨+肝动脉结扎(n=10);(G)丝裂霉素+碘油(对照组,n=10)。13d后再次进行MRI检查以确定肿瘤体积V2变化,比较肝肿瘤体积生长率V2/V1。结果介入治疗后肿瘤体积与治疗前肿瘤体积之比(V2/V1)分别为A组7.30、B组6.53、C组4.01、D组7.78、E组6.28、F组1.53、G组9.14。与对照组相比,采取B、C、E、F组的治疗方案能有效抑制肝肿瘤的生长(P<0.05),而采取A、D组的治疗方案在肿瘤生长率方面与对照组差异无显著性(P>0.05)。其中,F组的疗效最佳且未见肝内肿瘤转移。结论白芨作为肝动脉栓塞剂并结合化疗药和肝动脉结扎?钱骏 郑传胜 吴汉平 Daryusch Vossoughi Elsie Oppermann Vogl Thomas 冯敢生 2005中国医院药学杂志2005,25,5:20
2血管生成抑制剂烟曲霉素衍生物在介入治疗肝细胞癌实验中的应用显示文摘目的研究经肝动脉化疗栓塞术结合肝动脉灌注血管生成抑制剂合成的烟曲霉素衍生物(TNP470)治疗ACI大鼠肝细胞癌的疗效。方法在20只雄性ACI大鼠肝包膜下移植MorrisHepatoma3924A肝癌小瘤块(2mm3),移植术后第13天时进行MR检查,测量肿瘤体积V1,第14天时,在荷瘤大鼠经胃十二指肠动脉逆行插管至肝动脉而采取以下介入治疗方案:治疗组:碘化油(0.1ml)+丝裂霉素(0.1mg)+TNP470(5.0mg)(10只);对照组:碘化油(0.1ml)+丝裂霉素(0.1mg)(10只)。治疗后再次进行MR检查测量肿瘤体积V2,比较肝肿瘤体积变化(V2/V1)。结果治疗组和对照组大鼠经介入治疗前后的肝肿瘤平均体积分别为0.04cm3和0.15cm3以及0.04cm3和0.34cm3。治疗组和对照组肿瘤体积平均增长倍数(V2/V1)分别为4.11和9.14。与对照组相比,治疗组能明显抑制肝肿瘤体积的增长(P<0.01)。结论在ACI大鼠肝细胞癌模型,采用肝动脉化疗栓塞术结合肝动脉灌注血管生成抑制剂TNP470的治疗方法可明显抑制肝肿瘤体积的生长。钱骏 Vossoughi Daryusch Oppermann Elsie Vogl Thomas 冯敢生 2006中华放射学杂志2006,40,1:14
3Roles of Arabidopsis Patatin-Related Phospholipases A in Root Development Are Related to Auxin Responses and Phosphate Deficiency显示文摘Phospholipase A 酶劈开 phospho- 和 galactolipids 产生在发信号的动物和植物荷尔蒙工作的免费的丰满的酸和 lysolipids。这里,我们描述三 Arabidopsis patatin 相关的 phospholipase A (pPLA ) 基因 AtPLAIVA, AtPLAIVB,和 AtPLAIVC 和他们的相应蛋白质。Loss-of-function 异种在正常开发期间并且在磷酸盐剥夺下面在根为这些 pPLAs 揭示角色。AtPLAIVA 强烈并且专门在根被表示, AtplaIVA 空的异种减少了侧面的根开发,损害植物生长素回答特征。由对比, AtPLAIVB 在根,子叶,和叶子微弱地被表示,但是被植物生长素 transcriptionally 导致,尽管 AtplaIVB 异种通常发展。AtPLAIVC 在花的 gynaecium 被表示并且被 abscisic 酸(骆驼毛的织物) 或磷酸盐缺乏在根导致。当 AtplaIVC-1 loss-of-function 异种显示骆驼毛的织物应答时,它在根开发期间展出损害回答到磷酸盐缺乏。Recombinant AtPLA 蛋白质水解优先地 galactolipids 并且,不太高效地, phospholipids,尽管这些酶不在叶绿体是局部性的。我们发现 AtPLAIVA 和 AtPLAIVB 是由在 vitro 的钙依赖者蛋白质 kinases 的 phosphorylated,这在 phosphatidylcholine 上然而并非在 phosphatidylglycerol 上提高他们的活动。一起拿,数据在在磷酸盐缺乏并且植物生长素发信号之间的接口与单个角色在根开发揭示 pPLAs 的新奇函数。Steffen Rietz Georgi Dermendjiev Esther Oppermann Fikadu Getah Tafesse Yunus Effendi Andre Holk Jane E. Parker Markus Teige Gunther F.E. Scherer 2010Molecular Plant2010,3,3:7
4白芨在介入治疗大鼠肝细胞癌实验中的比较研究显示文摘肝癌是我国最常见的恶性肿瘤之一,经肝动脉化疗栓塞术(TACE)被公认为治疗不可切除性中、晚期肝癌的一种重要手段[1].本研究旨在通过建立肝细胞癌大鼠模型,在此模型上考察以白芨微粒作肝动脉栓塞剂并与抗肿瘤血管生成药物、免疫反应调节剂相比介入治疗大鼠肝细胞癌的疗效.钱骏 郑传胜 吴汉平 黎维勇 Vossoughi Daryusch Elsie Oppermann Thomas Vogl 冯敢生 2005中华肝脏病杂志2005,13,2:7
5白芨在经肝动脉化疗栓塞术治疗大鼠肝细胞癌实验中的应用显示文摘目的评价白芨在经肝动脉化疗栓塞术(transarterialchemoembolization,TACE)治疗ACI大鼠肝细胞癌实验中的应用价值。方法在30只ACI大鼠肝包膜下植入MorrisHepatom3924A肝癌瘤块(2mm3),移植术后13d进行MR检查,测量肿瘤体积(V1),第14天时,经大鼠胃十二指肠动脉逆行插管至肝动脉,采取以下治疗方案A组01mg丝裂霉素+01ml碘油+10mg白芨(10只);B组01mg丝裂霉素+01ml碘油+10mg白芨+肝动脉结扎(10只);C组01mg丝裂霉素+01ml碘油(对照组,10只)。13d后再次进行MR检查以测量肿瘤体积(V2),比较肝肿瘤体积生长率(V2/V1)。结果介入治疗后与治疗前肿瘤体积之比(V2/V1)分别为A组628,B组153,C组914。与对照组C相比,采取A、B组的治疗方案均能抑制肝肿瘤的生长(P<005和P<001),A组与B组之间的肿瘤生长率差异亦有统计学意义(P<001)。结论白芨作为肝动脉栓塞剂,结合局部化疗术和肝动脉结扎术能明显抑制大鼠肝细胞癌的生长。钱骏 吴汉平 郑传胜 黎维勇 Vossoughi Daryusch Oppermann Elsie Vogl Thomas 冯敢生 2005中华放射学杂志2005,39,3:4
6Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model显示文摘AIM: To compare the effect of transarterial chemoembolization(TACE) plus GRGDSP(Gly-Arg-Gly-Asp-SerPro, integrin-inhibitor) loaded nanoparticles with TACE alone or TACE + GRGDSP in a rat model of liver tumor. METHODS: Morris hepatoma 3924 A tumors were implanted in the livers of 30 ACI rats. The ACI rats were divided randomly into three groups(10 animals each). Tumor volume before treatment(V1) was examined by magnetic resonance imaging(MRI), and then, after laparotomy and placement of a PE-10 catheter into the hepatic artery, the following interventional protocols were performed: TACE(mitomycin C + lipiodol + degradable starch microspheres) + GRGDSP loaded nanoparticles for group A; TACE + GRGDSP for group B(control group 1); TACE alone for group C(control group 2). Tumor volume(V2) was assessed by MRI and the mean ratio of the post-treatment to pretreatment tumor volumes(V2/V1) was calculated. Immunohistochemical analysis was performed to assess the quantification of matrix metalloprotein 9(MMP-9) and vascular endothelial growth factor(VEGF) positive tumor cells in each treatment group.RESULTS: The mean tumor growth ratios(V2/V1) were 1.3649 ± 0.1194 in group A, 2.0770 ± 0.1595 in group B, and 3.2148 ± 0.1075 in group C. Compared with groups B and C, group A showed a significant reduction in tumor volume. Lower expression of MMP-9 and VEGF in hepatocellular carcinoma was observed in group A than in groups B and C. The angiogenesis of tumor was evaluated using anti-VEGF antibodies, and the metastasis of tumor was assessed using antiMMP-9 antibody. MMP-9 and VEGF were expressed in all specimens. The immunoexpression of these proteins was confirmed by the presence of red cytoplasmic staining in tumor cells. Lower expression of MMP-9 and VEGF in hepatocellular carcinoma was observed in group A than in groups B and C.CONCLUSION: Transarterial administration of integrin inhibitor loaded nanoparticles combined with TACE evidently retards tumor growth and intrahepatic metastases compared with TACE alone or TACE plus integrin inhibitor in an animal model of hepatocellular carcinoma.Jun Qian Elsie Oppermann Andreas Tran Ulli Imlau Kun Qian Thomas Josef Vogl 2016World Journal of Gastroenterology2016,22,21:2
7Convention Participation Decision- Making Process 显示文摘Martin Oppermann 1997Annals of Tourism Research1997,24,1:1
8The Intensive Care Delirium Screening Checklist (ICDSC)-translation and validation of intensive care delirium checklist in accordance with guidelines显示文摘Radtke FM Franck M Oppermann S 2009Anasthesiol Intensivmed Notfallmed Schmerzther2009,44,2:1
9Dislocation following total hip replacement显示文摘Dargel J Oppermann J Brüggemann GP 2014Dtsch Arztebl Int2014,11,5152:1
10Ionic liquids for two-phase systems and their application for purification, extraction and biocatalysis 显示文摘Oppermann S Stein F Kragl U 2011Applied Microbiology and Biotechnology2011,89,:1
11Intranational tourist flows in Malaysia 显示文摘Oppermann M 1992Annals of Tourism Research1992,19,3:1
12Periodontal attachment loss in an urban population of Brazilian adults:effect of demographic,behavioral,and environmental risk indlcators显示文摘Susin C DaUa Vecchia CF Oppermann RV 2004J Periodontal2004,75,7:1
13Predicting destination choice: A discussion of destination loyalty显示文摘Oppermann M 1999Journal of Vacation Marketing1999,5,1:1
14Clinical significance of anti - dsDNA antibody isotypes: IgG/IgM ratio of anti - dsDNA anti- bodies as a prognostic marker for lupus nephritis显示文摘Forger F Matthias T Oppermann M 2004Lupus2004,13,1:1
15Application of solid-phase mieroextraetion and gas chromatography with electron-capture and mass spectrometric detection for the determination of hexachlorocyclohexanes in soil solutions显示文摘Popp P Kalbitz K Oppermann G 1994Journal of Chromatography A1994,687,1:1
16Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis显示文摘Vallbracht I Rieber J Oppermann M 2004Ann Rheum Dis2004,83,:1
17Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus显示文摘 Mack M Proudfoot AE 1999J Biol Chem1999,274,13:1
18Destination threshold potential and the law of repeat visitation显示文摘Oppermann M 1998Journal of Travel Research1998,37,2:1
19Rural Tourism in Southern Germany显示文摘Oppermann Martin(1996) 1996Annals of Tourism Research1996,23,1:1
20Convention Cities hnages and Changing Fortunes 显示文摘Oppermann M 1996Journal of Tourism Studies1996,7,1:1
返回顶部 每页显示:
共26页 首页 上一页 第1页 下一页 末页 /26 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费